Skip to main content

Advertisement

Table 3 Baseline CTC characteristics of patients with prostate cancer according to vimentin and Ki67 CTC status

From: Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

Vimentin cohort  
 Number of pts with ≥1 CTC (%)
  Total CTC 80/93 (86)
  Vimentin CTC 30/93 (32.3)
 Number of pts with ≥5 CTC (%)
  Total CTC 69/93 (74.2)
  Vimentin CTC 10/93 (10.8)
 Number of pts with ≥5 CTC and ≥1 vimentin CTC 28/69 (40.6)
 Number of pts with only Vimentin-positive CTC 1/93 (1.1)
 Number of Vimentin-positive CTCs in total 960/26299 (3.7)
Ki67 cohort
 Number of pts with ≥1 CTC (%)  
  Total CTC 41/51 (80.4)
  Ki67 CTC 23/51 (45.1)
 Number of pts with ≥5 CTC (%)  
  Total CTC 35/51 (68.6)
  Ki67 CTC 12/51 (23.5)
 Number of pts with ≥5 CTC and ≥1 Ki67 CTC 22/35 (62.9)
 Number of pts with only Ki67-positive CTC 3/51 (5.9)
 Number of Ki67-positive CTCs in total 307/2495 (12.3)